These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 21841523)
21. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S Oncology; 2012; 83(1):1-9. PubMed ID: 22688083 [TBL] [Abstract][Full Text] [Related]
22. Disseminated progression of glioblastoma after treatment with bevacizumab. Bloch O; Safaee M; Sun MZ; Butowski NA; McDermott MW; Berger MS; Aghi MK; Parsa AT Clin Neurol Neurosurg; 2013 Sep; 115(9):1795-801. PubMed ID: 23706614 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of Surgery and Further Treatment of Progressive Glioblastoma. Woernle CM; Péus D; Hofer S; Rushing EJ; Held U; Bozinov O; Krayenbühl N; Weller M; Regli L World Neurosurg; 2015 Aug; 84(2):301-7. PubMed ID: 25797075 [TBL] [Abstract][Full Text] [Related]
24. Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis. Perrini P; Gambacciani C; Weiss A; Pasqualetti F; Delishaj D; Paiar F; Morganti R; Vannozzi R; Lutzemberger L J Neurooncol; 2017 Feb; 131(3):585-591. PubMed ID: 27844310 [TBL] [Abstract][Full Text] [Related]
25. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083 [TBL] [Abstract][Full Text] [Related]
26. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench. Burkhardt JK; Hofstetter CP; Santillan A; Shin BJ; Foley CP; Ballon DJ; Pierre Gobin Y; Boockvar JA J Clin Neurosci; 2012 Nov; 19(11):1568-72. PubMed ID: 22985932 [TBL] [Abstract][Full Text] [Related]
27. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy? Nakamura H; Murakami R; Hirai T; Kitajima M; Yamashita Y Acta Radiol; 2013 Mar; 54(2):214-20. PubMed ID: 23138021 [TBL] [Abstract][Full Text] [Related]
28. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565 [TBL] [Abstract][Full Text] [Related]
29. Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases. Tait MJ; Petrik V; Loosemore A; Bell BA; Papadopoulos MC Br J Neurosurg; 2007 Oct; 21(5):496-500. PubMed ID: 17852105 [TBL] [Abstract][Full Text] [Related]
30. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Mandl ES; Dirven CM; Buis DR; Postma TJ; Vandertop WP Surg Neurol; 2008 May; 69(5):506-9; discussion 509. PubMed ID: 18262245 [TBL] [Abstract][Full Text] [Related]
31. Repeat-surgery at Glioblastoma recurrence, when and why to operate? Ening G; Huynh MT; Schmieder K; Brenke C Clin Neurol Neurosurg; 2015 Sep; 136():89-94. PubMed ID: 26092644 [TBL] [Abstract][Full Text] [Related]
32. Survival after reoperation for recurrent glioblastoma. Woodroffe RW; Zanaty M; Soni N; Mott SL; Helland LC; Pasha A; Maley J; Dhungana N; Jones KA; Monga V; Greenlee JDW J Clin Neurosci; 2020 Mar; 73():118-124. PubMed ID: 31987636 [TBL] [Abstract][Full Text] [Related]
33. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. Burkhardt JK; Riina H; Shin BJ; Christos P; Kesavabhotla K; Hofstetter CP; Tsiouris AJ; Boockvar JA World Neurosurg; 2012 Jan; 77(1):130-4. PubMed ID: 22405392 [TBL] [Abstract][Full Text] [Related]
34. Residual tumor volume and patient survival following reoperation for recurrent glioblastoma. Yong RL; Wu T; Mihatov N; Shen MJ; Brown MA; Zaghloul KA; Park GE; Park JK J Neurosurg; 2014 Oct; 121(4):802-9. PubMed ID: 25061868 [TBL] [Abstract][Full Text] [Related]
35. Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue? Wachter D; Kallenberg K; Wrede A; Schulz-Schaeffer W; Behm T; Rohde V J Neurol Surg A Cent Eur Neurosurg; 2012 Nov; 73(6):401-6. PubMed ID: 22777926 [TBL] [Abstract][Full Text] [Related]
36. Impact of extent of resection and recurrent surgery on clinical outcome and overall survival in a consecutive series of 170 patients for glioblastoma in intraoperative high field magnetic resonance imaging. Coburger J; Wirtz CR; König RW J Neurosurg Sci; 2017 Jun; 61(3):233-244. PubMed ID: 26149222 [TBL] [Abstract][Full Text] [Related]
37. Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme. Burkhardt JK; Shin BJ; Schlaff CD; Riina H; Boockvar JA J Exp Ther Oncol; 2011; 9(3):183-6. PubMed ID: 22070049 [TBL] [Abstract][Full Text] [Related]
38. The effect of re-operation on survival in patients with recurrent glioblastoma. Franceschi E; Bartolotti M; Tosoni A; Bartolini S; Sturiale C; Fioravanti A; Pozzati E; Galzio R; Talacchi A; Volpin L; Morandi L; Danieli D; Ermani M; Brandes AA Anticancer Res; 2015 Mar; 35(3):1743-8. PubMed ID: 25750337 [TBL] [Abstract][Full Text] [Related]
39. Usefulness of Reintervention in Recurrent Glioblastoma: An Indispensable Weapon for Increasing Survival. Delgado-Fernandez J; Garcia-Pallero MÁ; Blasco G; Penanes JR; Gil-Simoes R; Pulido P; Sola RG World Neurosurg; 2017 Dec; 108():610-617. PubMed ID: 28939537 [TBL] [Abstract][Full Text] [Related]
40. The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET). Field KM; Phal PM; Fitt G; Goh C; Nowak AK; Rosenthal MA; Simes J; Barnes EH; Sawkins K; Cher LM; Hovey EJ; Wheeler H Cancer; 2017 Sep; 123(18):3576-3582. PubMed ID: 28678383 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]